CL2019001385A1 - Composición farmacéutica para evitar la adicción a opioides. - Google Patents

Composición farmacéutica para evitar la adicción a opioides.

Info

Publication number
CL2019001385A1
CL2019001385A1 CL2019001385A CL2019001385A CL2019001385A1 CL 2019001385 A1 CL2019001385 A1 CL 2019001385A1 CL 2019001385 A CL2019001385 A CL 2019001385A CL 2019001385 A CL2019001385 A CL 2019001385A CL 2019001385 A1 CL2019001385 A1 CL 2019001385A1
Authority
CL
Chile
Prior art keywords
patient
pharmaceutical composition
composition
opioid addiction
opioids
Prior art date
Application number
CL2019001385A
Other languages
English (en)
Spanish (es)
Inventor
Catherine Stehman-Breen
John Davis
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2019001385A1 publication Critical patent/CL2019001385A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CL2019001385A 2016-11-29 2019-05-22 Composición farmacéutica para evitar la adicción a opioides. CL2019001385A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662427365P 2016-11-29 2016-11-29

Publications (1)

Publication Number Publication Date
CL2019001385A1 true CL2019001385A1 (es) 2019-07-26

Family

ID=60766150

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001385A CL2019001385A1 (es) 2016-11-29 2019-05-22 Composición farmacéutica para evitar la adicción a opioides.

Country Status (18)

Country Link
US (2) US10736961B2 (enExample)
EP (1) EP3548082B1 (enExample)
JP (1) JP7071975B2 (enExample)
KR (1) KR20190090820A (enExample)
CN (1) CN110072549A (enExample)
AU (1) AU2017366870B2 (enExample)
BR (1) BR112019010331A2 (enExample)
CA (1) CA3045116A1 (enExample)
CL (1) CL2019001385A1 (enExample)
CO (1) CO2019005247A2 (enExample)
EA (1) EA201991283A9 (enExample)
IL (1) IL266640B (enExample)
MA (2) MA46951A (enExample)
MX (1) MX2019006013A (enExample)
MY (1) MY200701A (enExample)
PH (1) PH12019501087A1 (enExample)
WO (1) WO2018102294A1 (enExample)
ZA (1) ZA201902967B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839956A (zh) * 2018-08-10 2021-05-25 瑞泽恩制药公司 安全有效治疗膝和/或髋疼痛的药物组合物
US20250011408A1 (en) 2021-11-19 2025-01-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
EP4514849A1 (en) 2022-04-27 2025-03-05 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
RS53661B1 (sr) 2007-08-10 2015-04-30 Regeneron Pharmaceuticals, Inc. Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
KR101867279B1 (ko) 2010-10-06 2018-06-15 리제너론 파아마슈티컬스, 인크. 항―인터류킨―４ 수용체（ｉｌ－４ｒ） 항체를 함유하는 안정화된 제형

Also Published As

Publication number Publication date
CN110072549A (zh) 2019-07-30
AU2017366870A1 (en) 2019-06-06
JP2019535716A (ja) 2019-12-12
PH12019501087A1 (en) 2019-08-19
US10736961B2 (en) 2020-08-11
JP7071975B2 (ja) 2022-05-19
US20180147280A1 (en) 2018-05-31
US20210060159A1 (en) 2021-03-04
MA45890A1 (fr) 2020-02-28
KR20190090820A (ko) 2019-08-02
MA45890B2 (fr) 2022-10-31
EP3548082B1 (en) 2024-05-15
MY200701A (en) 2024-01-11
EA201991283A1 (ru) 2019-09-30
EP3548082A1 (en) 2019-10-09
CA3045116A1 (en) 2018-06-07
EA201991283A9 (ru) 2019-11-27
WO2018102294A1 (en) 2018-06-07
IL266640A (en) 2019-07-31
US11491222B2 (en) 2022-11-08
ZA201902967B (en) 2024-10-30
AU2017366870B2 (en) 2024-09-19
BR112019010331A2 (pt) 2019-10-22
IL266640B (en) 2022-09-01
MA46951A (fr) 2019-10-09
MX2019006013A (es) 2019-10-14
CO2019005247A2 (es) 2019-05-31

Similar Documents

Publication Publication Date Title
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
ES2944597T3 (es) Terapias con células efectoras inmunitarias de eficacia mejorada
CL2017002241A1 (es) Método de tratamiento de cáncer asociado con una mutación de ras
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
CO2018000809A2 (es) Anticuerpos para cd40
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
GT201800018A (es) Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2019009122A (es) ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).
CL2018003284A1 (es) Métodos de tratamiento de enfermedades autoinmunes usando linfocitos t alogénicos.
CL2019001385A1 (es) Composición farmacéutica para evitar la adicción a opioides.
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
CO2017007874A2 (es) Composiciones y métodos para metabolismo muscular mejorado
NZ735777A (en) Methods and compositions to inhibit symptoms associated with veisalgia
CL2019002802A1 (es) Anticuerpos biespecíficos anti-pd-l1-anti-tim-3.
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
BR112019011461A2 (pt) terapia celular à base de nk melhorada
CL2018001434A1 (es) Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
PE20170305A1 (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
CL2017001919A1 (es) Forma de dosificación de liberación controlada resistente a la liberación abrupta de la dosis.
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.